SGLT2i

Effect of SGLT2 inhibition on aging-related biomarkers in older obese adults with pre-diabetes

Purpose of this Study

The purpose of the research study is to evaluate whether older, obese adults with pre-diabetes can benefit from taking a drug called dapagliflozin (brand name FARXIGA) to reduce cellular damage, pro-inflammatory cells of aging also called “senescent cells,” and other known markers of biological aging.

You may qualify if:

  • Age 60 and older
  • Borderline diabetes
  • Obese

You may NOT qualify if:

  • Live in a nursing home or assisted living
  • Have diabetes
  • Have a chronic disabling disease
  • You are using medications for diabetes

Duration of the Study:

The study involves a total of 12 study visits over the course of approximately 4 to 5 months.

Study Procedures:

  • Medical history
  • Physical examination/assessment
  • Blood tests
  • Body composition (DEXA)
  • Liver ultrasound and MRS/MRI
  • Muscle and fat sampling
  • Heart and lung exercise test  & EKG (optional)

Study Location:

UT Health San Antonio
Sam and Ann Barshop Institute for Longevity and Aging Studies
4939 Charles Katz Dr.
San Antonio, TX 78229

UT Health San Antonio Research Imaging Institute
8403 Floyd Curl Drive
San Antonio, TX 78229

UT San Antonio Medical Arts & Research Center
8300 Floyd Curl Drive
San Antonio, TX 78229

Compensation:

Up to $470 is offered for the completion of this study.

Principal Investigator:

Carolina Solis-Herrera, MD

Contact Us

For more information or to volunteer in a study:

  • Call (210) 450-8097
  • If you prefer that we contact you, please fill out the form below.
Contact Us Clinical
reCAPTCHA